What is the tumors expressing CD56 and CD99?
Best insight from top research papers
CD56 and CD99 are expressed in various tumors. CD56 expression has been observed in gynecologic pathology, specifically in neuroendocrine, sex cord, and sex cord-like tumors . It has also been found to be positive in YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma . CD99 expression has been identified in Diffuse Midline glioma (DMG) and has shown potential as a therapeutic target for this refractory disease . Additionally, CD99 expression has been observed in uterine smooth muscle tumors, including leiomyosarcomas, leiomyomas, smooth muscle tumors of uncertain malignant potential, and intravenous leiomyomatoses . CD56 and CD99 have also been found to be positive in ectomesenchymal chondromyxoid tumors (ECTs), which are rare tumors that arise from uncommitted ectomesenchymal cells .
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
Open access•Journal Article 8 Citations | The paper does not mention anything about tumors expressing CD56 and CD99. The paper is about the diagnostic utility of CD56 in distinguishing between benign and malignant thyroid lesions. |
4 Citations | The paper does not mention CD99 expression in tumors. It only discusses CD56 expression in uterine smooth muscle tumors. |
| The paper does not mention tumors expressing CD56. The paper does mention that H3K27M-mutant expressing Diffuse Midline Gliomas (DMGs) have high expression of CD99. | |
14 Citations | YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma commonly expresses CD56 and CD99. |
Related Questions
Is cd64 expressed in pbmc?4 answersCD64 is expressed in PBMCs (Peripheral Blood Mononuclear Cells) as indicated by the research studies. The presence of CD64 in PBMCs has been linked to influencing the efficacy of certain treatments. Studies have shown that CD64 expression levels can impact the activity of anti-TNF therapies in inflammatory bowel disease patients, affecting the response to treatments like infliximab. Additionally, in the context of diagnosing infections, the CD64 index has been evaluated as a potential biomarker to differentiate between inflammation due to surgery and that due to infection, showcasing its utility in clinical settings. Therefore, CD64 expression in PBMCs plays a crucial role in various medical scenarios, from treatment response assessment to infection diagnosis.
Is cd58 expression linked to DLBCL outcome to Cart therapy?5 answersCD58 expression is indeed linked to the outcome of Diffuse Large B Cell Lymphoma (DLBCL) patients undergoing Chimeric Antigen Receptor (CAR) T cell therapy. Studies have shown that elevated CD58 expression in tumor samples of patients treated with CD19-specific CAR T cell therapy is associated with a complete clinical response and improved survival outcomes. Furthermore, research indicates that CD58 expression is upregulated in PDAC tissues and its high expression is notably related to poor survival of PDAC patients, suggesting its potential as a prognostic marker. Additionally, CD58 has been identified as a gene mutation that predicts poor clinical outcomes in DLBCL patients, emphasizing its critical impact on the prognosis and the need for tailored therapy for improved outcomes.
Is CD36 protein a target for cancer drug formulation?4 answersCD36 protein is a potential target for cancer drug formulation. It is highly expressed in various tumor types and is associated with advanced stages, poor prognosis, and reduced survival. CD36 plays a multifaceted role in cancer progression, including promoting fatty acid uptake, reprogramming lipid metabolism, enhancing cancer cell proliferation, and promoting epithelial-mesenchymal transition. CD36 is also implicated in cancer stemness, chemo- and radioresistance, and metastasis-initiating capability. Several approaches have been developed to target CD36, including blocking monoclonal antibodies, small-molecule inhibitors, and compounds that knock down CD36 expression. In preclinical studies, CD36 inhibitors have shown efficacy in reducing CD36-mediated functions in cancer cell cultures and animal models. Furthermore, CD36 inhibition has been shown to reduce metastasis and improve survival in acute myeloid leukemia (AML) mouse models. Overall, the evidence suggests that CD36 is a valid target for the development of new anti-cancer therapies.
What is the proportion of CD56 bright to CD56 dim NK cells in normal human blood?4 answersThe proportion of CD56 bright to CD56 dim NK cells in normal human blood is not explicitly mentioned in the abstracts provided.
Do ILC1 express CD56?5 answersILC1 do express CD56.
What do the nk cells positive for CD57 do?4 answersCD57+ NK cells are highly mature and terminally differentiated. They have a more mature phenotype, express a repertoire of NK-cell receptors, and exhibit higher cytotoxic capacity and sensitivity to stimulation via CD16. However, they have decreased responsiveness to cytokines and a decreased capacity to proliferate. CD57 expression on NK cells is associated with chronic infections, particularly human cytomegalovirus, and increases with age. CD57+ NK cells are beneficial in non-communicable diseases and contribute to graft-versus-leukemia reactions. CD57- NKG2C+ NK cells may represent a less differentiated, but readily expanding stage of the adaptive-like CD57+ NKG2C+ NK cells. CD57 expression can be induced on CD57-CD56dim NK cells after activation by interleukin-2.